NACLC 2022 | Optimizing outcomes in patients with cancer cachexia

Cancer cachexia is a syndrome characterized by loss of muscle mass, fat and weight. Occurring in half of patients with solid tumors, patients with this condition have worse outcomes with approximately a third of cancer deaths are attributed to cachexia. Puneeth Iyengar, MD, PhD, UT Southwestern Medical Center, Dallas, TX, talks on current and future treatment options for cachexia. There are currently no FDA approved treatments nor any known predicative biomarkers. JAK inhibitors are at present being investigated to suppress cancer cachexia in patients with non-small cell lung cancer (NSCLC). This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.